Literature DB >> 29336987

The in vitro radiosensitizer potential of resveratrol on MCF-7 breast cancer cells.

Isabel Cristina da Costa Araldi1, Fernando Primitivo Romero Bordin1, Francine Carla Cadoná2, Fernanda Barbisan2, Verônica Farina Azzolin2, Cibele Ferreira Teixeira2, Tadeu Baumhardt3, Ivana Beatrice Mânica da Cruz2, Marta Maria Medeiros Frescura Duarte4, Liliane de Freitas Bauermann5.   

Abstract

Radiation therapy is commonly applied in breast cancer (BC) patients. However, radioresistance and side effects are limiting factors of this practice. Therefore, studying substances that can enhance the radiation effect and, at the same time, protect normal cells is very relevant. Thus, the aim of this work was to assess the radiosensitizer effect of resveratrol (RV) on BC cells (MCF-7). A high cytotoxic and antiproliferative effect was observed in the treatment with 10 μM of RV + 3 Gy ionizing radiation (IR). Our results indicate that, 24 h after the exposition of cell cultures to RV + IR, an induction of necrosis/senescence has occurred. Furthermore, was observed the activation of extrinsic apoptosis pathway through a decrease of the Bax/Bcl-2 ratio and a high activity of caspase 8. Moreover, our data show that this treatment affected the oxidative cell metabolism, increasing oxidative protein, lipid and membrane damage and also acted to decrease the antioxidant enzymes activity. The antiproliferative effect on 72 h cultures may be associated with a high expression of p53 and an interruption of cell cycle in the S phase. Therefore, our results suggest that RV is a potential radiosensitizer of MCF-7 BC cells.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antioxidant; Breast cancer; Polyphenols; Radiomodifier; Radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 29336987     DOI: 10.1016/j.cbi.2018.01.013

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  7 in total

Review 1.  Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action.

Authors:  Mitra Behroozaghdam; Maryam Dehghani; Amirhossein Zabolian; Davood Kamali; Salar Javanshir; Farzaneh Hasani Sadi; Mehrdad Hashemi; Teimour Tabari; Mohsen Rashidi; Sepideh Mirzaei; Atefeh Zarepour; Ali Zarrabi; Danielle De Greef; Anupam Bishayee
Journal:  Cell Mol Life Sci       Date:  2022-10-04       Impact factor: 9.207

Review 2.  Effect of therapies-mediated modulation of telomere and/or telomerase on cancer cells radiosensitivity.

Authors:  Ganiou Assani; Yudi Xiong; Fuxiang Zhou; Yunfeng Zhou
Journal:  Oncotarget       Date:  2018-10-09

Review 3.  Nutraceutical Compounds as Sensitizers for Cancer Treatment in Radiation Therapy.

Authors:  Marco Calvaruso; Gaia Pucci; Rosa Musso; Valentina Bravatà; Francesco P Cammarata; Giorgio Russo; Giusi I Forte; Luigi Minafra
Journal:  Int J Mol Sci       Date:  2019-10-23       Impact factor: 5.923

Review 4.  Application of Radiosensitizers in Cancer Radiotherapy.

Authors:  Liuyun Gong; Yujie Zhang; Chengcheng Liu; Mingzhen Zhang; Suxia Han
Journal:  Int J Nanomedicine       Date:  2021-02-12

5.  Role of Resveratrol as Radiosensitizer by Targeting Cancer Stem Cells in Radioresistant Prostate Cancer Cells (PC-3).

Authors:  Sanaa A El-Benhawy; Mohmed I Morsi; Enayat I Fahmy; Moustafa A Soula; Fatma Al Zahraa Fh Khalil; Amal Refaat Arab
Journal:  Asian Pac J Cancer Prev       Date:  2021-12-01

Review 6.  Metabolic Rewiring in Radiation Oncology Toward Improving the Therapeutic Ratio.

Authors:  Marike W van Gisbergen; Emma Zwilling; Ludwig J Dubois
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

7.  The resveratrol analogue, HS‑1793, enhances the effects of radiation therapy through the induction of anti‑tumor immunity in mammary tumor growth.

Authors:  Joong Sun Kim; Soo Kyung Jeong; Su Jung Oh; Chang Geun Lee; Yeong Rok Kang; Wol Soon Jo; Min Ho Jeong
Journal:  Int J Oncol       Date:  2020-03-19       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.